Advancing treatment efficacy: combined therapy of eribulin, anlotinib, and camrelizumab in advanced or metastatic retroperitoneal liposarcoma

医学 艾瑞布林 不良事件通用术语标准 无进展生存期 内科学 实体瘤疗效评价标准 肿瘤科 养生 脂肪肉瘤 外科 不利影响 化疗 进行性疾病 肉瘤 癌症 转移性乳腺癌 病理 乳腺癌
作者
Weiwei Jia,Jianhui Wu,Hongtao Zhang,Yan Wu,Daoning Liu,Zhen Wang,Xiaopeng Wang,Cheng‐Peng Li,Chunyi Hao
出处
期刊:Therapeutic Advances in Medical Oncology [SAGE]
卷期号:16
标识
DOI:10.1177/17588359241276968
摘要

Background: Retroperitoneal liposarcoma (RLPS) typically shows limited response to standard chemotherapy, presenting a challenge in treating advanced or metastatic RLPS. Objective: This study aimed to evaluate the potential advantages of a combined therapeutic strategy utilizing eribulin, anlotinib, and camrelizumab. Design: Between December 2020 and March 2023, this retrospective study enrolled patients with advanced or metastatic RLPS who received treatment at Peking University Cancer Hospital Sarcoma Center. The treatment regimen involved eribulin plus anlotinib and camrelizumab administered every 3 weeks (Q3W). Methods: Efficacy was assessed following the Response Evaluation Criteria in Solid Tumors version 1.1, while safety was evaluated using the Common Terminology Criteria for Adverse Events version 5.0. Results: The study included 47 patients with RLPS with a median age of 55.5 years. Patients received a median of 4.5 (range, 2–21) cycles of treatment. Notably, partial response was observed in 8 patients (18.2%), while 25 (56.8%) exhibited stable disease. The objective response rate (ORR) and disease control rate were 18.2% and 75%, respectively. Significant differences in ORR were observed among histological subtypes (well-differentiated vs de-differentiated vs myxoid: 0 vs 17.9% vs 50%; p = 0.039). Six patients underwent surgery before disease progression, and one patient with myxoid liposarcoma (MLPS) had a pathological complete response. With a median follow-up of 21.8 (range, 2.7–30.7) months, the median progression-free survival (mPFS) was 6.9 (95% confidence interval (CI), 4.7–9.1) months, and the 6-month PFS rate was 60.5%. Based on various histological subtypes, the mPFS was 8.4 (95% CI, 4.1–12.7) months with well-differentiated liposarcoma, 5.8 (95% CI, 3.3–8.3) months with de-differentiated liposarcoma and not reached with MLPS, respectively. Treatment-related adverse events (TRAEs) of any grade occurred in 36 (76.6%) patients, with grade 3 or higher TRAEs in 21 (44.7%) patients. The most common TRAEs were neutropenia (53.2%), proteinuria (21.3%), and anorexia (21.3%). Conclusion: The combined treatment strategy involving eribulin, anlotinib, and camrelizumab showed promising efficacy and manageable safety in patients with advanced or metastatic RLPS, particularly in those with MLPS.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
了解完成签到,获得积分10
刚刚
lee发布了新的文献求助20
刚刚
上官若男应助淡淡的老头采纳,获得10
刚刚
NexusExplorer应助呆萌板凳采纳,获得10
1秒前
Jasper应助yoga敏采纳,获得10
1秒前
稳重飞飞完成签到,获得积分10
1秒前
1秒前
善学以致用应助冯昊采纳,获得10
1秒前
2秒前
欣喜代秋完成签到,获得积分10
3秒前
阿莱克修斯完成签到,获得积分20
3秒前
chem发布了新的文献求助10
3秒前
李健的小迷弟应助Lucy__Kuo采纳,获得10
3秒前
nature完成签到,获得积分10
3秒前
香菜大姐完成签到,获得积分10
4秒前
4秒前
顾矜应助风中的向卉采纳,获得10
5秒前
苹果行天发布了新的文献求助10
5秒前
林夕发布了新的文献求助10
7秒前
8秒前
8秒前
常常应助邓少龙采纳,获得10
9秒前
神勇的元灵完成签到,获得积分20
9秒前
调研昵称发布了新的文献求助10
10秒前
DamenS完成签到,获得积分10
10秒前
10秒前
10秒前
西西发布了新的文献求助10
10秒前
隐形曼青应助dj幸福旅行采纳,获得10
10秒前
Chickentui完成签到,获得积分10
11秒前
11秒前
坚定盈发布了新的文献求助20
11秒前
albatross完成签到,获得积分10
12秒前
12秒前
Orange应助自由灵枫采纳,获得10
13秒前
张文茜发布了新的文献求助20
13秒前
冯昊完成签到,获得积分10
13秒前
13秒前
13秒前
14秒前
高分求助中
Sustainability in Tides Chemistry 2000
The ACS Guide to Scholarly Communication 2000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 810
Pharmacogenomics: Applications to Patient Care, Third Edition 800
Ожившие листья и блуждающие цветы. Практическое руководство по содержанию богомолов [Alive leaves and wandering flowers. A practical guide for keeping praying mantises] 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3078684
求助须知:如何正确求助?哪些是违规求助? 2731454
关于积分的说明 7518586
捐赠科研通 2379920
什么是DOI,文献DOI怎么找? 1261966
科研通“疑难数据库(出版商)”最低求助积分说明 611803
版权声明 597369